{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:27:30Z","timestamp":1785788850314,"version":"3.56.0"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/mol.0b013e3283613b8b","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T15:31:41Z","timestamp":1366126301000},"page":"221-226","source":"Crossref","is-referenced-by-count":34,"title":["Statins and lipid metabolism"],"prefix":"10.1097","volume":"24","author":[{"given":"Stefania","family":"Lamon-Fava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20211004","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins.","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R2-7-20211004","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"for the JUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"R3-7-20211004","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCRESAHA.110.223883","article-title":"Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.","volume":"107","author":"Spite","year":"2010","journal-title":"Circ Res"},{"key":"R4-7-20211004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins.","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"R5-7-20211004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0165-6147(97)01147-4","article-title":"Hydrophilicitylipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.","volume":"19","author":"Hamelin","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"R6-7-20211004","doi-asserted-by":"crossref","first-page":"14490","DOI":"10.1016\/S0021-9258(19)85265-1","article-title":"Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence.","volume":"268","author":"Briggs","year":"1993","journal-title":"J Biol Chem"},{"key":"R7-7-20211004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0021-9150(01)00709-2","article-title":"Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors.","volume":"162","author":"Marsh","year":"2002","journal-title":"Atherosclerosis"},{"key":"R8-7-20211004","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0022-2275(20)35115-4","article-title":"Lovastatin enhances hepatic uptake of low density lipoprotein in humans.","volume":"34","author":"Kervinen","year":"1993","journal-title":"J Lipid Res"},{"key":"R9-7-20211004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0022-2275(20)42825-1","article-title":"Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.","volume":"31","author":"Arad","year":"1990","journal-title":"J Lipid Res"},{"key":"R10-7-20211004","first-page":"I135","article-title":"Effects of combined therapy with lovastatin and colestipol in heterozygous familial hypercholesterolemia. Effects on kinetics of apolipoprotein B.","volume":"9","author":"Vega","year":"1989","journal-title":"Arteriosclerosis"},{"key":"R11-7-20211004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0021-9150(88)90107-4","article-title":"Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.","volume":"70","author":"Vega","year":"1988","journal-title":"Atherosclerosis"},{"key":"R12-7-20211004","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/01.ATV.17.10.1910","article-title":"Lovastatin decreases de novo cholesterol synthesis and LDL apoB100 production rates in combined hyperlipidemic subjects.","volume":"17","author":"Cuchel","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R13-7-20211004","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1210\/jcem.87.5.8455","article-title":"Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.","volume":"87","author":"Chan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-7-20211004","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2007.03.004","article-title":"Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.","volume":"197","author":"Ooi","year":"2008","journal-title":"Atherosclerosis"},{"key":"R15-7-20211004","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1194\/jlr.M700067-JLR200","article-title":"Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism.","volume":"48","author":"Lamon-Fava","year":"2007","journal-title":"J Lipid Res"},{"key":"R16-7-20211004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"R17-7-20211004","doi-asserted-by":"crossref","first-page":"e1003058","DOI":"10.1371\/journal.pgen.1003058","article-title":"RHOA is a modulator of the cholesterol-lowering effects of statin.","volume":"8","author":"Medina","year":"2012","journal-title":"PLoS Genet"},{"key":"R18-7-20211004","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors.","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-7-20211004","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R20-7-20211004","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","article-title":"Sterol-dependent regulation of proprotein convertase subtilisinkexin type 9 expression by sterol-regulatory element binding protein-2.","volume":"49","author":"Jeong","year":"2008","journal-title":"J Lipid Res"},{"key":"R21-7-20211004","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jacc.2011.12.043","article-title":"Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.","volume":"59","author":"Huijgen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R22-7-20211004","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2362.1995.tb01746.x","article-title":"Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.","volume":"25","author":"Watts","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"R23-7-20211004","first-page":"E462","article-title":"Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.","volume":"273","author":"Watts","year":"1997","journal-title":"Am J Physiol"},{"key":"R24-7-20211004","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.metabol.2007.09.008","article-title":"Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.","volume":"57","author":"Hogue","year":"2008","journal-title":"Metabolism"},{"key":"R25-7-20211004","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0022-2275(20)30112-7","article-title":"Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.","volume":"43","author":"Chan","year":"2002","journal-title":"J Lipid Res"},{"key":"R26-7-20211004","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2362.2002.01012.x","article-title":"Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia.","volume":"32","author":"Dane-Stewart","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"R27-7-20211004","first-page":"650","article-title":"Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus Clin Endocrinol (Oxf","volume":"63","author":"Ng","year":"2005","journal-title":")"},{"key":"R28-7-20211004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-153-12-201012210-00006","article-title":"Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk.","volume":"153","author":"Jafri","year":"2010","journal-title":"Ann Intern Med"},{"key":"R29-7-20211004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-006-0063-3","article-title":"The effects of statins on high-density lipoproteins.","volume":"8","author":"Asztalos","year":"2006","journal-title":"Curr Atheroscler Rep"},{"key":"R30-7-20211004","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-8703(03)00440-X","article-title":"Effect on high-density lipoprotein cholesterol of maximum doses of simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).","volume":"146","author":"Ballantyne","year":"2003","journal-title":"Am Heart J"},{"key":"R31-7-20211004","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.atherosclerosis.2006.12.001","article-title":"POLARIS study investigatorsEfficacy and safety of rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesteolemia: results of the POLARIS study.","volume":"194","author":"Leiter","year":"2007","journal-title":"Atherosclerosis"},{"key":"R32-7-20211004","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1586\/erc.11.47","article-title":"Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis.","volume":"9","author":"Yokote","year":"2011","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"R33-7-20211004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9150(02)00149-1","article-title":"Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.","volume":"164","author":"Asztalos","year":"2002","journal-title":"Atherosclerosis"},{"key":"R34-7-20211004","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"STELLAR Study GroupComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial).","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"R35-7-20211004","first-page":"II","article-title":"Lovastatin increases apolipoprotein A-I levels in subjects with isolated reductions in high-density lipoproteins.","volume":"84","author":"Ginsberg","year":"1991","journal-title":"Circulation"},{"key":"R36-7-20211004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0021-9150(99)00053-2","article-title":"Metabolic basis of high-density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.","volume":"144","author":"Schaefer","year":"1999","journal-title":"Atherosclerosis"},{"key":"R37-7-20211004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2337\/diabetes.52.3.803","article-title":"Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.","volume":"52","author":"Watts","year":"2003","journal-title":"Diabetes"},{"key":"R38-7-20211004","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1194\/jlr.M300309-JLR200","article-title":"Effects of atorvastatin versus fenofibrate on apo B-100 and apo A-I kinetics in mixed hyperlipidemia.","volume":"45","author":"Bilz","year":"2004","journal-title":"J Lipid Res"},{"key":"R39-7-20211004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1124\/jpet.105.085522","article-title":"Influence of atorvastatin on apolipoprotein E and A-I kinetics in patients with type 2 diabetes.","volume":"315","author":"Bach-Ngohou","year":"2005","journal-title":"Pharmacol Exp Ther"},{"key":"R40-7-20211004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/ajcn\/84.1.37","article-title":"Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.","volume":"84","author":"Chan","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R41-7-20211004","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2007-0854","article-title":"Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.","volume":"93","author":"Ooi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-7-20211004","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1194\/jlr.P800040-JLR200","article-title":"Rosuvastatin 20mg restores normal HDL-apoA-I kinetics in type 2 diabetes.","volume":"50","author":"Verges","year":"2009","journal-title":"J Lipid Res"},{"key":"R43-7-20211004","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apo A-I.","volume":"107","author":"Martin","year":"2001","journal-title":"J Clin Investig"},{"key":"R44-7-20211004","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.metabol.2008.02.014","article-title":"Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in HepG2 cells.","volume":"57","author":"Qin","year":"2008","journal-title":"Metabolism"},{"key":"R45-7-20211004","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1194\/jlr.M200414-JLR200","article-title":"Role of hepatic ABCA1 transporter in mudulating intrahepatic cholesterol and plasma HDL cholesterol concentrations.","volume":"44","author":"Basso","year":"2003","journal-title":"J Lipid Res"},{"key":"R46-7-20211004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1254\/jphs.10241FP","article-title":"Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARalpha-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells.","volume":"116","author":"Maejima","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"R47-7-20211004","doi-asserted-by":"crossref","first-page":"21090","DOI":"10.1074\/jbc.M701228200","article-title":"Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status.","volume":"282","author":"Tamehiro","year":"2007","journal-title":"J Biol Chem"},{"key":"R48-7-20211004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1124\/jpet.105.093930","article-title":"Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP.","volume":"317","author":"Zanotti","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R49-7-20211004","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/FJC.0b013e318167141f","article-title":"Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway.","volume":"51","author":"Qiu","year":"2008","journal-title":"J Cardiovasc Pharmacol"},{"key":"R50-7-20211004","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/pgs.10.93","article-title":"Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.","volume":"11","author":"Genvigir","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R51-7-20211004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-511X-10-8","article-title":"Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.","volume":"10","author":"Song","year":"2011","journal-title":"Lipids Health Dis"},{"key":"R52-7-20211004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejphar.2011.04.043","article-title":"Regulation mechanism of ABCA1 expression by statins in hepatocytes.","volume":"662","author":"Kobayashi","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"R53-7-20211004","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"AV, Cuchel M, de lL-M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.","volume":"364","year":"2011","journal-title":"N Engl J Med"},{"key":"R54-7-20211004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.atherosclerosis.2007.07.007","article-title":"Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin.","volume":"197","author":"Sviridov","year":"2008","journal-title":"Atherosclerosis"},{"key":"R55-7-20211004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0b013e3283468061","article-title":"Metabolic and functional relevance of HDL subspecies.","volume":"22","author":"Asztalos","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"R56-7-20211004","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1161\/01.ATV.0000183727.90611.4f","article-title":"Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial.","volume":"25","author":"Asztalos","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R57-7-20211004","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.bbalip.2009.03.008","article-title":"Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: role of phospholipid transfer protein.","volume":"1791","author":"Dallinga-Thie","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"R58-7-20211004","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.atherosclerosis.2007.08.001","article-title":"Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE3-Leiden.CETP mice.","volume":"197","author":"de Haan","year":"2008","journal-title":"Atherosclerosis"},{"key":"R59-7-20211004","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1185\/03007995.2010.509264","article-title":"Effect of increasing doses of rosuvastatin and atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters.","volume":"26","author":"Karalis","year":"2010","journal-title":"Curr Med Res Opin"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T02:25:14Z","timestamp":1633314314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00007"}},"subtitle":["an update"],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e3283613b8b","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}